查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602792

抗缺血藥物市場：按類型、適應症、給藥途徑和最終用戶分類 - 全球預測 2025-2030

Anti-Ischemic Agents Market by Type (Antiplatelet Agents, Calcium Channel Blockers, Organic Nitrates), Indication (Angina Pectoris, Ischemic Stroke, Myocardial Infarction), Route of Administration, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗缺血藥物市值為35,588萬美元，預計2024年將達到37899萬美元，複合年成長率為6.23%，預計到2030年將達到54343萬美元。

抗缺血藥物是一種旨在改善心臟血流量和氧氣輸送並緩解心絞痛等缺血症狀的藥物。它們是一系列廣泛的治療方法，旨在控制冠狀動脈疾病、心臟病和其他限制心肌血流的心血管疾病。全球心血管疾病盛行率的上升凸顯了對抗缺血藥物的需求，心血管疾病是導致死亡的主要原因。抗缺血藥物在醫院、診所和門診治療中心有著廣泛的應用，循環系統經常使用它來預防心臟衰竭，並作為心臟病發作後的治療策略。最終用途範圍從改善急性護理中的患者治療效果到門診護理中的慢性管理。

主要市場統計
基準年[2023] 35588萬美元
預測年份 [2024] 37899萬美元
預測年份 [2030] 5.4343億美元
複合年成長率（%） 6.23%

市場成長受到文明病盛行率增加、藥物配方進步以及醫療保健支出增加等因素的影響。個人化醫療的創新以及雷諾嗪和Ivabradine等新治療類別的出現為市場擴張提供了機會。醫療保健系統不斷發展的新興市場也具有巨大的市場滲透潛力。然而，市場面臨嚴格的監管要求、高昂的研發成本以及替代療法（包括血管成形術等侵入性手術）的可用性等挑戰。

創新的機會在於開發功效較強、副作用較少、作用機轉新穎的藥物。生技藥品和基因療法為未來的研究和開發帶來了希望。將數位健康技術與抗缺血治療相結合也是一個新興的創新領域，有可能提高患者的依從性和治療結果。您可以透過專注於特定的未滿足需求開拓利基市場，例如罕見的缺血性疾病，在該領域，現有製藥公司在競爭格局中佔據主導地位。總體而言，市場仍然充滿活力，技術進步和人口變化為顯著的業務成長和持續的研究工作提供了管道。

市場動態：揭示快速發展的抗缺血藥物市場的關鍵市場洞察

供需的動態交互作用正在改變抗缺血藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 生活方式的改變和缺血性疾病盛行率的上升
    • 更多地使用先進的診斷工具和技術來治療缺血性疾病
    • 開發新型抗缺血藥物的研究活動激增
  • 市場限制因素
    • 治療費用上漲
  • 市場機會
    • 藥物開發活動的持續創新與投資
    • 臨床試驗中各相關人員之間的合作
  • 市場挑戰
    • 相關副作用與安全性問題

波特五力：駕馭抗缺血藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗缺血藥物市場的外部影響

外部宏觀環境因素在塑造抗缺血藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗缺血藥物市場競爭狀況

抗缺血藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV定位矩陣抗缺血劑市場供應商績效評估

FPNV定位矩陣是評估抗缺血藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪抗缺血藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，抗缺血藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 生活方式的改變和缺血性疾病發生率的增加
      • 更多使用先進的缺血性疾病診斷工具和技術
      • 旨在開發新型抗缺血藥物的研究活動迅速增加
    • 抑制因素
      • 治療費用高
    • 機會
      • 藥物開發活動的持續創新與投資
      • 臨床試驗中各相關人員的合作
    • 任務
      • 相關副作用與安全性問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 抗缺血藥物市場：依類型

  • 抗血小板藥
  • 鈣離子通道阻斷劑
  • 有機硝酸鹽
  • 鉀通道開放劑
  • B阻斷劑

第7章 抗缺血藥物適應症市場

  • 心絞痛
  • 缺血性中風
  • 心肌梗塞
  • 周邊動脈疾病

第8章抗缺血藥物市場：依給藥途徑

  • 靜脈注射 (IV)
  • 口服
  • 經皮的

第9章抗缺血藥物市場：依最終用戶分類

  • 門診治療
  • 居家護理
  • 醫院

第10章 美洲抗缺血藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區抗缺血藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲抗缺血藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alembic Pharmaceuticals Limited
  • AstraZeneca
  • Baxter, Inc.
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Cipla Ltd.
  • Dr Reddy's Laboratories Ltd.
  • Eli Lily & Company
  • Eris Lifesciences Ltd.
  • FDC Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd.
  • Ipca Laboratories Ltd.
  • JB Chemicals and Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Macleods Pharmaceuticals Pvt Ltd.
  • Medley Pharmaceuticals Ltd.
  • Micro Labs Ltd.
  • Natco Pharma Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Torrent Pharmaceuticals Ltd.
  • Troikaa Pharmaceuticals Ltd.
  • Zydus Lifesciences Ltd.
Product Code: MRR-8E22B6193309

The Anti-Ischemic Agents Market was valued at USD 355.88 million in 2023, expected to reach USD 378.99 million in 2024, and is projected to grow at a CAGR of 6.23%, to USD 543.43 million by 2030.

Anti-ischemic agents are pharmaceuticals designed to improve blood flow and oxygen supply to the heart, alleviating symptoms of ischemia such as angina. The scope of these agents encompasses a range of therapeutic applications aimed at managing coronary artery disease, heart attacks, and other cardiovascular conditions where blood flow to the heart muscle is restricted. The necessity for anti-ischemic agents is underscored by the rising prevalence of cardiovascular diseases globally, which are the leading cause of mortality. Their application spans hospitals, clinics, and ambulatory care centers, often utilized by cardiologists to prevent heart failure or in management strategies post-heart attack. The end-use scope extends from enhancing patient outcomes in acute care settings to chronic management in outpatient care.

KEY MARKET STATISTICS
Base Year [2023] USD 355.88 million
Estimated Year [2024] USD 378.99 million
Forecast Year [2030] USD 543.43 million
CAGR (%) 6.23%

Market growth is influenced by factors such as increasing incidence of lifestyle diseases, advancements in drug formulation, and rising healthcare expenditures. Innovations in personalized medicine and the advent of novel therapeutic classes, such as ranolazine and ivabradine, present opportunities for expanding the market. Emerging markets, with growing healthcare systems, also offer significant potential for market penetration. However, the market faces challenges like stringent regulatory requirements, high research and development costs, and the availability of alternative treatments, including invasive procedures like angioplasty.

Opportunities for innovation lie in developing drugs with better efficacy, fewer side effects, and novel mechanisms of action. Biologics and gene therapy hold promise for future research and development. Combining digital health technologies with anti-ischemic treatments also represents a burgeoning area for innovation, potentially improving patient adherence and outcomes. Despite the competitive landscape dominated by established pharmaceutical companies, niche markets can be explored by focusing on specific unmet needs, such as rare ischemic conditions. Overall, the market remains dynamic, with technological advancements and shifting demographics providing channels for significant business growth and sustained research efforts.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Ischemic Agents Market

The Anti-Ischemic Agents Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Changing lifestyles and rising prevalence of ischemic conditions
    • Increasing utilization of advanced diagnostic tools and techniques for ischemic conditions
    • Surge in research activities for developing new anti-ischemic agents
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Ongoing innovations and investment in drug development activities
    • Collaborative efforts among various stakeholders for clinical trials
  • Market Challenges
    • Associated side-effects and safety concerns

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Ischemic Agents Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Ischemic Agents Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Ischemic Agents Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Ischemic Agents Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Ischemic Agents Market

A detailed market share analysis in the Anti-Ischemic Agents Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Ischemic Agents Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Ischemic Agents Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Ischemic Agents Market

A strategic analysis of the Anti-Ischemic Agents Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Ischemic Agents Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, AstraZeneca, Baxter, Inc., Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Cipla Ltd., Dr Reddy's Laboratories Ltd., Eli Lily & Company, Eris Lifesciences Ltd., FDC Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., J B Chemicals and Pharmaceuticals Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Medley Pharmaceuticals Ltd., Micro Labs Ltd., Natco Pharma Ltd., Novartis AG, Pfizer, Inc., Torrent Pharmaceuticals Ltd., Troikaa Pharmaceuticals Ltd., and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Ischemic Agents Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Antiplatelet Agents, Calcium Channel Blockers, Organic Nitrates, Potassium Channel Openers, and B-Blockers.
  • Based on Indication, market is studied across Angina Pectoris, Ischemic Stroke, Myocardial Infarction, and Peripheral Artery Diseases.
  • Based on Route of Administration, market is studied across Intravenous (IV), Oral, and Transdermal.
  • Based on End-User, market is studied across Ambulatory Care, Homecare, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Changing lifestyles and rising prevalence of ischemic conditions
      • 5.1.1.2. Increasing utilization of advanced diagnostic tools and techniques for ischemic conditions
      • 5.1.1.3. Surge in research activities for developing new anti-ischemic agents
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing innovations and investment in drug development activities
      • 5.1.3.2. Collaborative efforts among various stakeholders for clinical trials
    • 5.1.4. Challenges
      • 5.1.4.1. Associated side-effects and safety concerns
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Ischemic Agents Market, by Type

  • 6.1. Introduction
  • 6.2. Antiplatelet Agents
  • 6.3. Calcium Channel Blockers
  • 6.4. Organic Nitrates
  • 6.5. Potassium Channel Openers
  • 6.6. B-Blockers

7. Anti-Ischemic Agents Market, by Indication

  • 7.1. Introduction
  • 7.2. Angina Pectoris
  • 7.3. Ischemic Stroke
  • 7.4. Myocardial Infarction
  • 7.5. Peripheral Artery Diseases

8. Anti-Ischemic Agents Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous (IV)
  • 8.3. Oral
  • 8.4. Transdermal

9. Anti-Ischemic Agents Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Care
  • 9.3. Homecare
  • 9.4. Hospitals

10. Americas Anti-Ischemic Agents Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anti-Ischemic Agents Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anti-Ischemic Agents Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alembic Pharmaceuticals Limited
  • 2. AstraZeneca
  • 3. Baxter, Inc.
  • 4. Bayer AG
  • 5. Boehringer Ingelheim
  • 6. Bristol Myers Squibb
  • 7. Cipla Ltd.
  • 8. Dr Reddy's Laboratories Ltd.
  • 9. Eli Lily & Company
  • 10. Eris Lifesciences Ltd.
  • 11. FDC Ltd.
  • 12. Glenmark Pharmaceuticals Ltd.
  • 13. Intas Pharmaceuticals Ltd.
  • 14. Ipca Laboratories Ltd.
  • 15. J B Chemicals and Pharmaceuticals Ltd.
  • 16. Lupin Ltd.
  • 17. Macleods Pharmaceuticals Pvt Ltd.
  • 18. Medley Pharmaceuticals Ltd.
  • 19. Micro Labs Ltd.
  • 20. Natco Pharma Ltd.
  • 21. Novartis AG
  • 22. Pfizer, Inc.
  • 23. Torrent Pharmaceuticals Ltd.
  • 24. Troikaa Pharmaceuticals Ltd.
  • 25. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTI-ISCHEMIC AGENTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-ISCHEMIC AGENTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTI-ISCHEMIC AGENTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTI-ISCHEMIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-ISCHEMIC AGENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-ISCHEMIC AGENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORGANIC NITRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY POTASSIUM CHANNEL OPENERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY B-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ANGINA PECTORIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PERIPHERAL ARTERY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. ANTI-ISCHEMIC AGENTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. ANTI-ISCHEMIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2023